A novel microfluidic device to predict brain cancer prognosis and response to therapy

Project: Research project

Project Details


PROJECT NARRATIVE In the United States, glioblastoma (GBM), the most common brain cancer, is responsible for over 13,000 deaths per year with an economic burden of $7.2 billion. Despite radical surgery and chemo-/radiotherapy, median survival for this lethal brain cancer is only 14.6 months. Given this dismal prognosis and paucity of effective treatment options, we aim to establish a novel device, Microfluidic Invasion Network Device (MIND), for clinical assessment of outcomes in GBM patients, genetic characterization of aggressive tumor behaviors and high-throughput screening of novel potential therapeutic drugs, with the potential to greatly impact the therapeutic management of patients with malignant brain tumors.
Effective start/end date2/14/181/31/23


  • National Cancer Institute: $424,954.00
  • National Cancer Institute: $1,914,224.00


Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.